Compare RGP & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | CLNN |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.3M | 120.6M |
| IPO Year | 2006 | N/A |
| Metric | RGP | CLNN |
|---|---|---|
| Price | $4.83 | $6.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.00 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 349.9K | 283.4K |
| Earning Date | 01-02-2026 | 11-13-2025 |
| Dividend Yield | ★ 5.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $534,625,000.00 | $214,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.75 | $87.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.13 | $2.28 |
| 52 Week High | $9.96 | $13.50 |
| Indicator | RGP | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 55.71 | 34.10 |
| Support Level | $4.71 | $8.90 |
| Resistance Level | $4.89 | $9.92 |
| Average True Range (ATR) | 0.20 | 1.14 |
| MACD | 0.02 | -0.27 |
| Stochastic Oscillator | 81.48 | 3.81 |
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.